A dose-finding study of CpG 7909 in previously treated chronic lymphocytic leukemia.
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Agatolimod (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.